<DOC>
	<DOCNO>NCT02803905</DOCNO>
	<brief_summary>The study phase 2 , monocentric , open-label study . The investigator recruit 12 patient T1D randomly ( 1:1 ) assign receive islet either liver portal venous circulation ( standard procedure ; arm A , n=6 ) directly omentum ( arm B , n=6 ) . Patients select eligible islet Tx base local practice guideline . Immunosuppression consist five dos IV infusion rabbit Anti-thymocyte Globulin ( ATG , Thymoglobulin® ) , start two day prior islet transplant . Maintenance mycophenolate mofetil ( MMF ) therapy ( 1-2 g/day BID dosing ) start Day -1 pre-transplant . Tacrolimus administer orally twice daily Day 1 post-transplant maintain trough level 10-12 ng/mL 3 month , 6-10 ng/mL thereafter . Etanercept give IV islet transplant ( 50 mg ) , 25 mg ( subcutaneously ) POD +3 , +7 +10 .</brief_summary>
	<brief_title>Islet Transplant Alone OMENtum</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Ability provide write informed consent . Mentally stable able comply procedure study protocol . Clinical history compatible T1D onset disease &lt; 40 year age , insulindependence &gt; 5 year time enrollment , sum subject age insulindependent diabetes duration ≥28 . Absent stimulate cpeptide ( &lt; 0.3ng/mL ) response MMTT Involvement intensive diabetes management At least one episode severe hypoglycemia 12 month prior study enrollment . Reduced awareness hypoglycemia define Clarke score 4 OR HYPO score great equal 90th percentile ( 1047 ) screen period ; OR mark glycemic lability characterize wide swing BG despite optimal diabetes therapy define LI score great equal 90th percentile ( 43 mmol/L2/h·wk1 ) screening period ; OR composite Clarke score 3 less HYPO score great equal 75th percentile ( 423 ) LI great equal 75th percentile ( 329 ) screening period . Body Mass Index ( BMI ) &gt; 30 kg/m2 patient weight ≤50 kg . Insulin requirement &gt; 1.0 IU/kg/day &lt; 15 U/day . HbA1c &gt; 10 % . Untreated proliferative diabetic retinopathy . Blood Pressure : SBP &gt; 160 mmHg DBP &gt; 100 mmHg . Measured glomerular filtration rate &lt; 80 mL/min/1.73 m2 . Presence history macroalbuminuria ( &gt; 300mg/g creatinine ) . Presence history panelreactive antiHLA antibody background flow cytometry . For female subject : Serum urine Positive pregnancy test , presently breastfeed , unwillingness use effective contraceptive measure duration study 4 month discontinuation . For male subject : intent procreate duration study within 4 month discontinuation unwillingness use effective measure contraception . Presence history active infection include hepatitis B , hepatitis C , HIV , tuberculosis ( TB ) . Subjects laboratory evidence active infection exclude even absence clinical evidence active infection . Negative screen EpsteinBarr Virus ( EBV ) IgG determination . Invasive aspergillus , histoplasmosis , coccidioidomycosis infection within one year prior study enrollment . Any history malignancy except completely resect squamous basal cell carcinoma skin . Baseline Hb low limit normal local laboratory ; lymphopenia ( &lt; 1,000/µL ) , neutropenia ( &lt; 1,500/µL ) , thrombocytopenia ( platelet &lt; 100,000/µL ) A history Factor V deficiency . Any coagulopathy medical condition require longterm anticoagulant therapy ( e.g. , warfarin ) transplantation ( lowdose aspirin treatment allow ) patient international normalized ratio ( INR ) &gt; 1.5 . Severe coexist cardiac disease Persistent elevation liver function test time study entry . Symptomatic cholecystolithiasis . Acute chronic pancreatitis . Symptomatic peptic ulcer disease . Hyperlipidemia despite medical therapy Receiving treatment medical condition require chronic use systemic steroid , except use ≤5 mg prednisone daily , equivalent dose hydrocortisone , physiological replacement . Treatment antidiabetic medication insulin within 4 week enrollment . Use investigational agent within 4 week enrollment . 24 . Administration live attenuate vaccine ( ) within 2 month enrollment . Inflammatory bowel disease . History intestinal obstruction . Previous major abdominal surgery . History peritonitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>